39 results about "Streptococcal strain" patented technology

This invention is in the field of bacterial cultures and specifically relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from Streptococcus strains in fed batch culture and to novel purification methods suitable for production scale purification of bacterial capsular polysaccharides from Streptococcus strains resulting in higher levels of purity than previously obtained for production scale.

The present invention features an array capable of monitoring gene expression patterns of multiple strains of Streptococcus pneumoniae including a substrate having a plurality of addresses, each of which has a probe disposed thereon.

Novel Enterococcus and Streptococcus bacteriocins produced by novel Enterococcus and Streptococcus strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.

The present invention discloses strains of Lactobacillus and Streptococcus which have a capacity to degrade gliadin peptides involved in coeliac disease and which peptide degrading activity is stable under low pH and in the presence of mammalian digestive enzymes. These strains are suitable in a product for use in prevention and/or treatment of celiac disease.

A pharmaceutical preparation for prophylaxis against and treatment of Staphylococcus induced infections or conditions in humans and animals, is disclosed, wherein it comprises a combination of a) one or more viable α-Streptococcus strains chosen from the group consisting of the Streptococcus sanguis II strains having the accession numbers NCIMB 40104, NCIMB 40105, NCIMB 40106, and NCIMB 40873, the Streptococcus mitis strains having the accession numbers NCIMB 40107, and NCIMB 40874, the Streptococcus oralis strains having the accession numbers NCIMB 40875 and NCIMB 40876, the Streptococcus lactis strain L1A having the accession number NCIMB 40157, and one or more variants thereof having the same or essentially similar effect; and b) one or more viable Lactobacillus strains chosen from the group consisting of the Lactobacillus rhamnosus strain LB21 having the accession number NCIMB 40564, the Lactobacillus plantarum strain LB3 having the accession number DSM 17852, and the Lactobacillus plantarum strain LB7 having the accession number DSM 17853, and one or more variants thereof having the same or essentially similar effect; in at least one pharmaceutically acceptable medium in which said strains maintain their viability, as well as a kit for and a method of prophylaxis and treatment of Staphylococcus induced infections and conditions, and use

Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INVl 04B)) identified in Streptococcus pneumoniae isolate INVl 04. In other aspects the polypeptides include pili polypeptides and non-pilus polypeptides from Streptococcus pneumoniae strains 23F, INV200, and OXC141 that are absent from Streptococcus pneumoniae isolate INV104. The polypeptides, including fragments and variants thereof, may be used in immunogenic compositions for prophylactic or therapeutic immunization against Streptococcus pneumoniae. The polypeptides are also disclosed to be used in compositions useful for the production of antibodies and immunostimulants. Also presented are methods of inhibiting Streptococcus pneumoniae, methods of treating Streptococcus pneumoniae infection, methods of identifying inhibitors of Streptococcus pneumoniae and methods for diagnosing/detecting Streptococcus pneumoniae infection.

The present invention relates to a Streptococcus thermophilus strain, wherein the strain is galactose-fermenting, wherein the strain carries a mutation in the DNA sequence of the glcK gene encoding a glucokinase protein, wherein the mutation inactivates the glucokinase protein or has a negative effect on expression of the gene, and wherein the strain carries a mutation in the promoter region of the GalK gene encoding a galactokinase protein.

The invention relates to the technical field of mutation breeding of lactic acid bacteria, and provides a method for breeding weak post-acidification streptococcus thermophilus strains. The method comprises the following steps: S1, preparation of a bacterial suspension: culturing an original strain to obtain a bacterial solution, transferring and continuously culturing the bacterial solution to a logarithmic metaphase, centrifuging, washing and concentrating the bacterial solution to obtain the suspension, and placing the suspension in an empty plate for later use; S2, ultraviolet irradiation: placing the suspension under an ultraviolet lamp for irradiation; S3, rejuvenation culture: resuspending the bacteria obtained in S2 in a fresh culture medium for rejuvenation culture; S4, penicillin treatment: adding penicillin for treatment, performing dilution, and coating an MC culture medium with the solution for culture; and S5, screening weak post-acidification strains. According to the technical scheme, the problem that the weak post-acidification streptococcus thermophilus strain cannot be efficiently bred in the prior art is solved.

The invention discloses a preparation method of whey protein, and relates to the technical field of microbial fermentation. The preparation method of the whey protein comprises the following steps: (1) preparing a mixed seed solution, specifically, respectively taking a bifidobacterium lactis strain and a streptococcus acidophilus strain, firstly performing constant-temperature culture, then inoculating the bifidobacterium lactis strain and the streptococcus acidophilus strain into a seed culture medium for amplification culture, then performing shake culture to respectively obtain a bifidobacterium lactis seed solution and a streptococcus acidophilus seed solution, and mixing the bifidobacterium lactis seed solution with the streptococcus acidophilus seed solution to obtain the mixed seed solution; and (2) performing fermentation, specifically, mixing the mixed seed solution obtained in the step (1) with a fermentation substrate, and performing fermentation to obtain the whey protein, wherein the fermentation substrate is a whey protein solution.

Novel Enterococcus and Streptococcus bacteriocins produced by novel Enterococcus and Streptococcus strains are used for at least reducing the level of colonization of at least one target bacteria in animals, particularly poultry.

Novel Enterococcus and Streptococcus bacteriocins produced by novel Enterococcus and Streptococcus strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.

The invention relates to a genetic cluster of strains of Streptococcus thermophilus, which have a lysotype distinct from that of the strains currently used. Within this cluster novel acidifying and lexturizing strains have been identified.

The present invention relates to a Siphoviridae bacteriophage Str-SUP-2 (Accession number: KCTC 13515BP) isolated from nature and characterized by having the ability to kill Streptococcus suis and having the genome represented by SEQ ID NO: 1, and a method for preventing and treating diseases caused by Streptococcus suis using the composition containing the Siphoviridae bacteriophage Str-SUP-2 as an active ingredient.

The invention provides recombinant Streptococcus mutans strains that can be used to improve oral health. An embodiment of the invention provides a method of reducing the incidence or severity of dental caries in a dental caries-susceptible host comprising administering orally to the host an isolated recombinant S. mutans strain of the invention in an amount effective for replacement of dental caries-causing S. mutans host strains in the oral cavity of the host. The isolated recombinant S. mutans strain 10 can be contained in a mouthwash, toothpaste, chewing gum, floss, chewable tablet, food, or beverage.

The invention relates to streptococcus thermophilus and application thereof. The streptococcus thermophilus is named as Streptococcus thermophilus URTOOI strain, wherein the preservation unit is ChinaGeneral Microbiological Culture Collection Center; the preservation time is April 13, 2020, the preservation number is CGMCC No.19575, and the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The streptococcus thermophilus strain has remarkable prevention and treatment effects on oral diseases, can remarkably inhibit adhesion of streptococcus gordonii or streptococcus mutans on hydroxyapatite, can remarkably reduce the thickness and density of a biological membrane formed by the streptococcus mutans on the hydroxyapatite, and can regulate oral flora. The strain is of great significance to prevention and control of oral health and oral diseases.

The invention relates to the technical field of microbial fermentation, in particular to a streptococcus thermophilus IMAU80287Y strain and use thereof, and yoghourt and a preparation method thereof. The provided streptococcus thermophilus IMAU80287Y strain has the deposit number of CGMCC No.22260. The provided IMAU80287Y strain has a good fermentation performance and can metabolize galactose. The provided IMAU80287Y strain has improved metabolism capacity of lactose and galactose by 6.2% and 25% respectively in a cow milk fermentation period and a cow milk storage period compared with those of an original strain. The yoghourt obtained through fermentation by IMAU80287Y has water holding capacity obviously higher than that of original strain-fermented milk, and ha a good fermentation performance.

The invention relates to the technical field of animal medicine, in particular to a streptococcus strain and a vaccine for preventing and treating swine streptococcosis. The invention provides streptococcus suis type 2, streptococcus suis type 7 and streptococcus suis type 9 obtained by screening, and the three strains can generate relatively high protection capability on streptococcus suis no matter whether the three strains are used for preparing the vaccine independently or in a mixed mode. Especially, trivalent vaccines prepared from the bacillus subtilis and the bacillus subtilis do not interfere with each other, and can safely and effectively play a good protection role in attack of three pathogenic bacteria.

The invention discloses a fermentation culture medium for producing hyaluronic acid by using a streptococcus strain. The fermentation culture medium comprises 70-90 g/L of sucrose, 10-20 g/L of cassava starch hydrolysate, 10-15 g/L of yeast powder, 3-5 g/L of corn steep liquor hydrolysate, 1-1.5 g/L of magnesium sulfate, 2-3 g/L of potassium dihydrogen phosphate , 4-6 g/L of disodium hydrogen phosphate, 10-20 mg/L of calcium chloride, 1-1.5 mg/L of copper sulfate, 6-15 mg/L of manganese sulfate, 0.1-1 g/L of a defoaming agent and the balance of water. The invention also discloses a culture method for producing hyaluronic acid through fermenting by using the streptococcus strain in the fermentation culture medium. The fermentation culture medium and the fermentation method can improve the yield and quality of hyaluronic acid, and are suitable for industrial production.